pre-IPO biotech

Oricell's $110 Million Bet Exposes the Dirty Secret of Solid Tumor CAR-T: The Science Is Ahead of the Business Model

Article: Opinion

Oricell’s $110 Million Bet Exposes the Dirty Secret of Solid Tumor CAR-T: The Science Is Ahead of the Business Model

Oricell Therapeutics just closed a $110 million pre-IPO round to push its CAR-T platform into solid tumors. Investors are...

By Moe Alsumidaie
April 10, 2026

Read More